Welcome to the Advanced Therapy Medicinal Products and Biologics Focus Group
Our Focus Group explores the development, manufacture, regulation and clinical use of advanced therapy medicinal products (ATMPs). This includes medicinal products that are based on gene therapy, somatic cell therapy or tissue engineering.
We bring together individuals from a range of disciplines from academia to industry to reflect the unique challenges that are presented by this exciting area of pharmaceutical sciences and welcomes those who are interested in this area.
What are Advanced Therapy Medicinal Products and Biologics (ATMPs)?
Advanced Therapy Medicinal Products and Biologics (ATMPs) include new therapeutic products that are typically based on gene therapy somatic cell therapy or tissue engineering. It presents new opportunities for the therapeutic resolution of medical problems that have either been beyond the scope of traditional small molecule drugs or they may offer a more effective treatment regimen. It also presents new challenges in our understanding of design, analysis, manufacture, dosing, delivery and biological monitoring of this complex group of medicines.
Take a look at our promotional video on YouTube
Advanced Therapy Medicinal Products and Biologics (ATMPs) Webinars
Take a look at the first in our Cell and Gene Therapies Video Interviews.
Dr Julian Braybrook became the Government Chemist in June 2018. He is currently Director of Measurement Science for the National Measurement Laboratory at LGC, a life sciences research and testing company, where he is responsible for the science strategy and partnership development of metrology (measurement science) and regulatory analysis programmes, in support of the UK National Measurement System.
Julian joined LGC in 1988 and has carried out a variety of roles, delivering and managing national and European analytical research innovation and contract service solutions for a wide range of chemical and biotechnology applications. He has a degree in Chemistry from the University of London and a PhD from the University of Cambridge for research into novel contrast agents for magnetic resonance spectroscopy and imaging. Julian has an honorary DSc from Kingston University London for his contributions to chemistry, is a Chartered Chemist and Fellow of the Royal Society of Chemistry (CChem FRSC).
Take a look at the second in our Cell and Gene Therapies Video Interviews.
Professor Fiona Thistlethwaite is an honorary professor at The University of Manchester. She graduated from The University of Cambridge MB PhD programme in 1999. Her PhD, under the supervision of Professor Sir Martin Evans, explored the molecular mechanisms that lead to cancer in inherited breast cancer syndromes.
Following training posts at Liverpool Royal, The Royal Marsden and The Christie, she became a consultant at The Christie in 2007. Her clinical practice is in Experimental Cancer Medicine and immune-oncology and her academic focus is clinical trial development in immunotherapy and adoptive T-cell therapy.
Fiona leads the Manchester health consortium, iMATCH, which was awarded almost £9 million by Innovate UK to ensure that more patients benefit from a new generation of advanced cell therapies. She is the Medical Director of the Christie Clinical Research Facility which delivers over 400 clinical trials to cancer patients.
Meet the Group
Focus Group Leads
Focus Group Members
Why You Should Get Involved
Do you work or have any specialist knowledge or interest in this area? If so, then we would love you to
join us and contribute to our plans.
We would like to undertake a review of current education provision of Advanced Therapy Medicinal Products and Biologics in the delivery of the Pharmacy and Pharmaceutical Science degree and secure sponsorship for Essay competition entitled Towards Patient-centred Biotherapeutics
